Jeffrey Karr

Of Counsel
Full contact info

Experience

Biotech Company ViaCyte to Be Acquired by Vertex Pharmaceuticals

July 14, 2022

Cooley advised ViaCyte, a biotechnology company focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for Type 1 diabetes (T1D), on its definitive agreement to be acquired by global biotechnology company Vertex Pharmaceuticals for $320 million in cash. Partners Rowook Park and Carlos Ramirez, along with associate Lindsey O’Crump, led the Cooley team advising ViaCyte.

Read more

Related contacts

Rowook Park
Partner, San Diego
Carlos Ramirez
Partner, San Diego
Jacqueline Grise
Partner, Washington, DC
Rama Padmanabhan
Partner, San Diego
Marty Schenker
Senior Counsel , San Francisco
Todd Gluth
Partner, San Diego
Blake Martell
Partner, San Francisco
Charity Williams
Partner, San Diego
Jeffrey Karr
Of Counsel, Palo Alto
Ross Eberly
Partner, Los Angeles Santa Monica
Phil Mitchell
Partner, New York
Natasha Leskovsek
Of Counsel, Washington, DC
David Burns
Special Counsel, Washington, DC
Dina Andrawess
Special Counsel, Palo Alto
Stella Sarma
Special Counsel, Brussels
Arman Sagart
Associate, San Diego
Lindsey O'Crump
Associate, Washington, DC
Melissa Meza
Associate, San Diego
Joe Mandry
Associate, San Diego
Julia R. Brinton
Associate, Washington, DC
Kimberley Scimeca
Associate, Boston
Daniel Lac
Associate, San Diego
Amanda Griggs
Associate, New York

Related Practices & Industries

Cooley Obtains Summary Judgment for Qualcomm in Patent Infringement Lawsuit

April 5, 2022

Cooley achieved a significant victory for longtime client Qualcomm when US District Judge Paul G. Byron of the US District Court for the Middle District of Florida granted the firm’s motion for summary judgment in a contested patent infringement lawsuit, ParkerVision v. Qualcomm. Lawyers Stephen Smith, Matthew Brigham, Eamonn Gardner, Dena Chen, Jeffrey Karr, Priya Viswanath and Benjamin Lin led the Cooley team advising Qualcomm. Brigham and Gardner argued the motion for summary judgment, with assistance from the larger team.

Read more

Related contacts

Stephen Smith
Partner, Washington, DC
Matthew Brigham
Of Counsel, Palo Alto
Eamonn Gardner
Partner, Colorado
Dena Chen
Partner, Palo Alto
Jeffrey Karr
Of Counsel, Palo Alto
Priya B. Viswanath
Special Counsel, Palo Alto
Stephen Neal
Chairman Emeritus, Palo Alto
Kathleen Goodhart
Partner, San Francisco
Erin Trenda
Partner, San Diego
Rich Nieva
Senior Paralegal, Palo Alto
Cassandra Reed
Paralegal Specialist, Palo Alto

Related Practices & Industries

Cooley Secures Interim Arbitration Award in Favor of Javo Beverage Company

July 13, 2021

Cooley secured an arbitration win for Javo Beverage Company in a contractual dispute against its former co-founder Stephen Corey involving theft of Javo’s intellectual property. The arbitrator, retired Judge Jay C. Gandhi, issued an interim arbitration award on July 6, following a five-day remote hearing that involved live testimony from 10 witnesses and hundreds of exhibits. Partners Steve Strauss, Jeffrey Karr and Erin Trenda led the Cooley team representing Javo.

Read more

Related contacts

Steve Strauss
Senior Counsel, San Diego
Jeffrey Karr
Of Counsel, Palo Alto
Erin Trenda
Partner, San Diego
Dane Voris
Special Counsel, Boston
Rachael Heller
Associate, San Diego
Jonathan Phillips
Senior Paralegal, San Diego

Related Practices & Industries

Complete win for Gilead Sciences in dispute involving breakthrough SOVALDI treatment

July 1, 2014

When F. Hoffmann-La Roche sought to strip Gilead of its rights to a blockbuster drug, Gilead turned to Cooley. At stake were Gilead's exclusive rights to sofosbuvir (Sovaldi), approved by the FDA in 2013 as a breakthrough drug for the treatment of hepatitis C. Within the first six months of going to market, Sovaldi earned nearly $6 billion in sales, making it one of the most successful drug launches in history.

Roche alleged exclusive rights based on an earlier collaboration agreement. Cooley presented this "bet the company" case before a panel of three arbitrators during a two-week arbitration hearing. In August 2014, the arbitration panel issued its award, ruling in favor of Gilead and finding that Roche failed to establish any of its contract or patent-based claims to sofosbuvir. This was a huge win for Gilead, with Sovaldi generating billions of dollars in revenue each year.

The Financial Times, The American Lawyer and its sister publications The Recorder and National Law Journal all profiled the victory when announcing Cooley as the winner of multiple litigation awards, including AmLaw's recent selection of the case as "Global Dispute of the Year: Commercial Arbitration."

Related contacts

Stephen Neal
Chairman Emeritus, Palo Alto
Marty Schenker
Senior Counsel , San Francisco
Dr. Michelle Rhyu
Partner, Palo Alto
Jeffrey Karr
Of Counsel, Palo Alto
Daniel Knauss
Partner, Palo Alto

Related Practices & Industries

Memberships & affiliations

State Bar of California